“DPP-IV inhibitors are widely used, well-tolerated antidiabetic agents that offer several advantages in clinical settings, especially for medically fragile populations, owing to their favorable efficacy and safety profile,” the researchers told Endocrine Today. “However, there is a concern that DPP-IV inhibitors may adversely impact the exocrine pancreas, owing to their pleiotropic effects. Read more . . .
Adults with type 2 diabetes who are treated with DPP-IV inhibitors are more likely to develop pancreatitis and pancreatic cancer compared with those treated with other medications, according to findings published in Diabetes Care.